The role of angiogenesic cytokines in systemic lupus erythematosus pathogenesis;Rola cytokin angiogennych w patogenezie układowego tocznia rumieniowatego

Acta Haematologica Polonica

Volumn 37, Issue 1, 2006, Pages 47-59

  Robak, Ewa ^a   Kulczycka, Liliana ^a   Tomczak, Joanna ^a   Sysa Jȩdrzejowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Angiogenic cytokines; Systemic lupus erythematosus

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; AUTOIMMUNE DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; ENVIRONMENTAL FACTOR; HEREDITY; HORMONE ACTION; HUMAN; IMMUNOPATHOLOGY; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 33744482542     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
2. Schroeder JO, Euler HH. Recogniton and management of systemic lupus erythematosus. Drugs 1997; 54: 422-434.
3. Mills JA. Systemic lupus erythematosus [review]. N Engl J Med 1994; 330: 1871-1879.
4. Samborski W, Żaba R. Nowe pogla̧dy na temat patogenezy tocznia rumieniowatego układowego - objawy kliniczne, rozpoznanie i leczenie. PdA 2001; 18: 5-10.
5. Swaak AJ, Nossent JC, Smeenk RJT. Systemic lupus erythematosus. Int J Clin Lab Res 1992; 22: 190-195.
6. Kluz J, Adamiec R, Tubek S. Rola przeciwcialł przeciwko komórkom śródbłonka w patogenezie naczyniowych powikłań układowego tocznia rumieniowatego. Pol Arch Med. Wewn 2004; 111: 727-734.
7. Polverini PJ. Angiogenesis in health and diseases: insights into basic mechanisms and therapeutic opportunities. J Dent Educ 2002; 66: 962-975.
8. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002; 6: 357-376.
9. Szekanecz Z, Szegedi G, Koch AE. Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Investig Med 1998; 46: 27-34.
10. Song J, Park YB, Lee Wki, Lee KH, Lee SK. Clinical associations of anti-edothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int 2000; 20: 1-7.
11. Spinger TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: multistep paradigm. Cell 1994; 76: 301-314.
12. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
13. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996; 88: 3259-3287.
14. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.
15. Robak E, Sysa-Jȩdrzejowska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus Mediat Inflamm. 2003; 12: 293-298.
16. Robak E, Woźniacka A, Sysa-Jȩdrzejowska A, Stȩpień H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002; 11: 348-355.
17. Woźniacka A. Preparaty antymalaryczne w leczeniu tocznia rumieniowatego. Przegl Lek 2002; 59: 179-182.
18. Samborski W. Farmakoterapia tocznia rumieniowatego układowego - nowe kierunki i metody eksperymentalne. PdiA 2004; 21: 30-35.
19. Aringer M, Smolen JS. Tumor necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004; 13: 344-347.
20. Shapiro R, Strydom DJ, Olsonb KA, Valee BL. Isolation of angiogenin from normal human plasma. Biochemistry 1987; 26: 5141-5146.
21. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 1986; 25: 3527-3532.
22. Hu GF, Riordan JF. Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 1993; 19: 682-687.
23. Weiner HL, Weiner LH, Swain JL. Tissue distribution and development expression of messenger RNA encoding angiogenin. Science 1987; 237: 280-281
24. Lyons RM, Gentry LE, Purchio AAF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990; 110: 1361-1367.
25. Olson KA, Verselis SJ, Fett JW. Angiogenin is regulated in vivo as an acute phase protein. Biochem Biophys Res Commun 1998; 242: 480-483.
26. Tschesche H, Kopp C, Horl WH, Hempelmann U. Inhibition of degranulation of polymononuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 1994; 269: 3274-3280.
27. Matousek J, Soucek J, Riha J, Zankel TR, Benner SA. Immunosupressive activity of angiogenin in comparison with bovine seminal rybonuclease and pancreatic rybonuclease. Comp Biochem Physiol 1995; 112: 235-241.
28. Verselis SJ, Olson KA, Fett JW. Regulation of angiogenin expression in human HepG2 hepatoma cells by mediators of the acute-phase response. Biochem Biophys Res Commun 1999; 259: 178-184.
29. Hu GF, Riordan JF, Vallee BL. A putative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc Natl Acad. Sci USA 1997; 94: 2204-2209.
30. Hu GF, Riordan JF, Vallee BL. An agiogenin-binding protein from endothelial celss. Proc Natl Acad Sci USA 1991; 88; 2227-2231.
31. Moroianu J, Riordan JF. Nuclear translocation of angiogenin in proliferating endothelial cells is essentiale to its angiogenic activity. Proc Natl Acad Sci USA 1994; 91: 1677-1681.
32. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu G. Endogenous angiogenin in endotelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005; 24: 445-456.
33. Studnicka-Benke A, Steienr G, Petera P, Smolen JS. Tumor necrosis factor alpha and it's soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol. 1996; 35: 1067-1074.
34. Robak E. The serum concentrations of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα) and their soluble receptors in relation to clinical activity of systemic lupus erythematodes. Anna Acad Med Lodz. 1999; suppl. 33: 213-215.
35. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-580.
36. Tokano Y, Morimoto S, Kanneko H et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE) - relation to Th1 and Th2 derived cytokines. Clin Exp Immunol 1999; 116: 1107-1118.
37. Robak E, Trzcińska E, Smolewski P. Komórki dendrytyczne we krwi obwodowej chorych na układowy toczeń rumieniowaty. Acta Haematol Pol. 2004; 35: 351-362.
38. Wong CK, Ho CY, Li EK, Lam CWK. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-593.
39. Aringer M, Stummvoll, Steiner G i wsp. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 2001; 40: 876-881.
40. Robak E, Robak T, Woźniacka A, Żak-Prelich M, Sysa-Jȩdrzejowska A, Stȩpień H. Proinflammatory interferon-γ-iducing monokines (interleukin-12, interleukin-18, interleukin-15) - serum profile in patients with systemic lupus erythematosus. Eur Cytokine Netw 2002; 13: 364-368.
41. O'Reillly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. 1997; 8: 277-285.
42. Ergun S, Kilic N, Wurmbach JH i wsp. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001; 4: 193-206.
43. Jiang L, Jha V, Dhanabal M, Sukhatme VP, Alper SL. Intacellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors enostatin and angiostatin. Am J Physiol Cell Physiol 2000; 280: 1140-1150.
44. Matsuno H, Yudoh K, Uzuki M, i wsp. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J Rheumatol 2002; 29: 262-266.